Actuate Therapeutics (NASDAQ:ACTU) Trading 0.8% Higher - What's Next?

Key Points

• Actuate Therapeutics (NASDAQ:ACTU) stock increased by 0.8% to $7.25, despite a 35% decline in trading volume compared to its average.
• Analysts have given the company a consensus rating of "Moderate Buy" with a price target averaging around $20.33, with several firms rating it "buy" while one has a "sell" rating.
• The company reported a quarterly loss of ($0.30) per share, missing analysts' expectations of ($0.19) per share.

Actuate Therapeutics, Inc. (NASDAQ:ACTU - Get Free Report) traded up 0.8% during mid-day trading on Thursday . The stock traded as high as $7.39 and last traded at $7.25. 45,708 shares traded hands during mid-day trading, a decline of 35% from the average session volume of 70,613 shares. The stock had previously closed at $7.19.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Actuate Therapeutics in a research note on Tuesday, September 23rd. Wall Street Zen upgraded shares of Actuate Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, September 20th. B. Riley assumed coverage on shares of Actuate Therapeutics in a research report on Tuesday, August 26th. They set a "buy" rating and a $20.00 price objective on the stock. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Actuate Therapeutics in a research report on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $20.33.

Actuate Therapeutics Price Performance

The business's 50-day simple moving average is $7.54 and its 200-day simple moving average is $7.94.

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.11).

Institutional Investors Weigh In On Actuate Therapeutics

Large investors have recently modified their holdings of the stock. Chicago Partners Investment Group LLC bought a new stake in shares of Actuate Therapeutics during the 1st quarter valued at about $70,000. Sfmg LLC bought a new position in shares of Actuate Therapeutics in the first quarter worth approximately $74,000. Bank of America Corp DE lifted its stake in shares of Actuate Therapeutics by 61,068.0% in the second quarter. Bank of America Corp DE now owns 15,292 shares of the company's stock worth $93,000 after buying an additional 15,267 shares in the last quarter. New York State Common Retirement Fund bought a new position in shares of Actuate Therapeutics in the second quarter worth approximately $105,000. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in shares of Actuate Therapeutics by 492.6% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 18,518 shares of the company's stock worth $113,000 after buying an additional 15,393 shares in the last quarter.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.